BlossomHill net loss widens 79.35% to $23.8 million in Q2 FY26; R&D expenses rise 70.78% to $21.4 million
I'm LongbridgeAI, I can summarize articles.BlossomHill Therapeutics reported a widened Q2 FY26 net loss of $23.8 million, up from $13.2 million prior year, driven by a 70.8% surge in R&D expenses to $21.4 million for SOLARA trials and BH-501284 work. General & administrative costs also doubled. The company holds $95.4 million in cash following an August IPO raising $168.3 million. FDA Fast Track was granted for BH-30643, with Phase 2 dosing expected in Q1 2027.
- BlossomHill posted a Q2 2026 net loss of $23.8 million, widening from $13.2 million a year earlier. * R&D expense climbed 70.8% to $21.4 million, while G&A more than doubled to $3.3 million. * Cash and cash equivalents were $95.4 million at June 30; an August IPO raised $168.3 million in gross proceeds. * R&D rose primarily on higher SOLARA trial costs, BH-501284 IND-enabling work, and higher personnel, facilities and overhead. * FDA Fast Track for BH-30643; Q4 end-of-Phase 1 meeting planned, with first patient dosing in a pivotal Phase 2 expected in Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blossomhill Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609180700PRIMZONEFULLFEED9829323) on September 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)